Press Releases

Antimicrobial Resistance

Specific Diagnostics acquisition

bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.

Financial Information

First-Quarter 2022 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2022.

Business & Solutions

bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system

bioMérieux, a world leader in the field of in vitro diagnostics, announces that VITEK® MS PRIME, its new MALDI-TOF mass spectrometry identification system, has received 510(k) clearance from the U.S. ...

Financial Information

bioMérieux – 2021 Financial Results

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 1 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial st...

Business & Solutions

MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics

bioMérieux, a world leader in the field of in vitro diagnostics, launches MYACUTECASETM. This mobile application, the first of a kind developed by bioMérieux, is an aid in the interpretation of VIDAS®...

Partnerships

French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance

The ARPEGE project aims to develop a set of solutions to strengthen the ability of healthcare institutions to fight antibiotic resistance. The consortium, led by Antabio, has been awarded close to €9 ...

Corporate Social Responsibility

Corporate Social Responsibility: bioMérieux recently received a series of official recognitions from independent third parties

bioMérieux, a world leader in the field of in vitro diagnostics, recently received a series of official recognitions for its achievements in Corporate Social Responsibility (CSR) from independent thir...

Financial Information

bioMérieux – Increased outlook for full-year 2021

bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2021. In light of stronger than expected respiratory panels sales in Q4, full-year 20...

Business & Solutions

bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant

As the incidence of infections with the SARS-CoV-2 Omicron variant (B.1.1. 529) continues to rise, there is much concern about diagnostic tests ability to efficiently detect this multi-mutated form of...

Partnerships

Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 test to predict persistent severe acute kidney injury

Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. T...

bioMérieux – Third-Quarter 2021 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2021.

A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities

On World Sepsis Day, bioMérieux, a world leader in the field of in vitro diagnostics, and the UK Sepsis Trust, an internationally renowned charity committed to help put an end to preventable deaths fr...

bioMérieux – First-Half 2021 Results

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 31 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statemen...

bioMérieux launches EPISEQ® SARS-COV-2, a cloud-based software application for the epidemiological surveillance of SARS-CoV-2 variants

bioMérieux, a world leader in the field of in vitro diagnostics, has launched EPISEQ® SARS-COV-2, a genomic software solution to support microbiology labs in identification and reporting from raw sequ...

In the fight against Antimicrobial Resistance, bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe

Marcy l’Étoile, France and Mountain View, California – bioMérieux, a world leader in the field of in vitro diagnostics, and Specific Diagnostics, a company bringing unique in vitro diagnostic systems ...